Cancer Genetics’ Proprietary IVD for Cervical Cancer, FHACT®, Receives CE Mark
By Italia on September 2 2014
> CE marking allows CGIs DNA-FISH Probe, FHACT®, to be widely marketed in European Economic Area, which covers 31 countries RUTHERFORD, N.J., September 02, 2014 Cancer Genetics, Inc. (Nasdaq; CGIX) (CGI or The Company), an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT®) has received the CE […]
Continue Reading